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Abstract
Patients with multiple myeloma commonly develop focal osteolytic bone disease, as well as generalised osteoporosis. The
mechanisms underlying the development of osteoporosis in patients with myeloma are poorly understood. Although
disruption of the RANKL/OPG pathway has been shown to underlie formation of focal osteolytic lesions, its role in the
development of osteoporosis in myeloma remains unclear. Increased soluble RANKL in serum from patients with myeloma
raises the possibility that this molecule plays a key role. The aim of the present study was to establish whether sRANKL
produced by myeloma cells contributes directly to osteoporosis. C57BL/KaLwRij mice were injected with either 5T2MM or
5T33MM murine myeloma cells. 5T2MM-bearing mice developed osteolytic bone lesions (p,0.05) with increased osteoclast
surface (p,0.01) and reduced trabecular bone volume (p,0.05). Bone volume was also reduced at sites where 5T2MM cells
were not present (p,0.05). In 5T2MM-bearing mice soluble mRANKL was increased (p,0.05), whereas OPG was not altered.
In contrast, 5T33MM-bearing mice had no changes in osteoclast surface or trabecular bone volume and did not develop
osteolytic lesions. Soluble mRANKL was undetectable in serum from 5T33MM-bearing mice. In separate experiments, RPMI-
8226 human myeloma cells were transduced with an human RANKL/eGFP construct, or eGFP alone. RPMI-8226/hRANKL/
eGFP cells, but not RPMI-8226/eGFP cells, stimulated osteoclastic bone resorption (p,0.05) in vitro. Sub-cutaneous injection
of NOD/SCID mice with RPMI-8226/hRANKL/eGFP or RPMI-8226/eGFP cells resulted in tumour development in all mice.
RPMI-8226/hRANKL/eGFP-bearing mice exhibited increased serum soluble hRANKL (p,0.05) and a three-fold increase in
osteoclast number (p,0.05) compared to RPMI-8226/eGFP-bearing mice. This was associated with reduced trabecular bone
volume (27%, p,0.05), decreased trabecular number (29%, p,0.05) and increased trabecular thickness (8%, p,0.05). Our
findings demonstrate that soluble RANKL produced by myeloma cells causes generalised bone loss, suggesting that
targeting RANKL may prevent osteoporosis in patients with myeloma.
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Introduction
An important clinical feature of multiple myeloma is the
development of a bone disease characterised by the presence of
osteolytic lesions, bone pain and pathological fractures. Patients
with myeloma also develop generalised bone loss, or osteoporosis,
independent of the focal osteolytic bone lesions [1]. There is a two-
fold increase in risk of osteoporotic fractures in patients with
myeloma [2] and individuals with monoclonal gammopathy of
underdetermined significance have an increased risk of axial
fractures prior to development of myeloma [3]. Although it is
widely recognised that increased osteoclastic resorption accounts
for the development of osteolytic bone disease, the cellular and
molecular mechanism responsible for the generalised bone loss is
poorly understood. Furthermore, studies aimed at clarifying the
importance of osteoporosis in the bone disease associated with
multiple myeloma, as well as the mechanism(s) involved, will help
provide the rationale for targeting this component of the disease.
The identification of the ligand for receptor activator of NFkB
(RANKL) [4,5,6], and the demonstration that RANKL plays a
critical role in normal osteoclast formation [7], raises the
possibility that abnormal expression of this molecule may stimulate
osteoclast formation and bone resorption in myeloma. RANKL
expression is increased in bone marrow stromal cells in patients
with myeloma [8,9] and may also be expressed directly by both
murine and human myeloma cells [10,11,12,13,14]. Furthermore,
RANKL may be upregulated in T lymphocytes derived from the
bone marrow of patients with myeloma [15]. The soluble decoy
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receptor for RANKL, osteoprotegerin (OPG), prevents RANKL-
association with receptor activator of NFkB (RANK) and blocks
osteoclast formation and bone resorption [10]. Studies have
demonstrated that myeloma cells down-regulate OPG production
in stromal cells and osteoblasts in a contact dependent manner
[8,9,16] and that serum concentrations of OPG are decreased in
patients with myeloma [17,18,19]. Furthermore, targeting
RANKL can prevent the development of myeloma bone disease
demonstrating that RANKL plays a pivotal role [9,10,20,21].
RANKL exists principally as a membrane-bound molecule,
although a soluble form (sRANKL) is generated by either
proteolytic processing, or alternative mRNA splicing [22,23,24].
The soluble form of RANKL can induce osteoclastogenesis in vitro
[5,25] and may be produced by T cells isolated from patients with
myeloma [15]. Furthermore, myeloma cells have been shown to
express the mRNA encoding the sRANKL isoform [23] and
increases in the concentration of sRANKL, and the ratio of
sRANKL/OPG, have both been detected in the serum of patients
with multiple myeloma. However, the importance of sRANKL
and its role in the development of osteoporosis associated with
myeloma bone disease remains unclear. Therefore, the aim of the
present study was to determine whether sRANKL causes
osteoporosis in murine models of multiple myeloma.
Materials and Methods
The 5T2MM and 5T33MM Models of Myeloma
The 5T2MM and 5T33MM murine models of myeloma
originated spontaneously in C57BL/KaLwRij mice [26,27].
5T2MM or 5T33MM cells were isolated from bone marrow of
disease-bearing animals, purified and injected into recipient mice
[28]. These models closely reflect many aspects of the disease seen
in humans. For example, they include the growth of myeloma in
bone, the dependency of the myeloma on the bone microenvi-
ronment for its growth and survival, the development of a
paraprotein that reflects myeloma burden and, in the case of
5T2MM, the characteristic osteolytic bone disease. Animals were
housed under conventional conditions and had free access to food
and tap water. All procedures involving these mice were approved
by the local ethics committee at the Free University of Brussels
(Belgium). Male C57BL/KaLwRij mice were injected with either
5T2MM or 5T33MM cells, or left un-injected (naı¨ve). Serum
paraprotein was monitored using standard electrophoretic tech-
niques throughout the development of the disease [29]. All
animals, including the respective uninjected, non-tumour bearing,
control groups, were sacrificed at 12 weeks for the 5T2MM
Figure 1. 5T2MM, but not 5T33MM cells cause osteolytic bone disease and tumour-induced bone loss. A. Reconstructed 3-dimensional
micro-CT images of the tibia of naı¨ve mice, mice bearing 5T2MM cells and mice bearing 5T33MM cells. Lesions in the tibia of 5T2MM bearing animals
are arrowed. B. Transverse sections of micro-CT images of tibiae from naı¨ve mice, mice bearing 5T2MM cells and mice bearing 5T33MM cells. Lesions
are arrowed. C. Radiographs of the tibia of naı¨ve mice, mice bearing 5T2MM cells and mice bearing 5T33MM cells. Lesions are arrowed. D. Number of
lesions in the tibia of naı¨ve mice and 5T2MM or 5T33MM bearing mice. E. Trabecular bone area as a proportion of total tissue area in the tibia of naı¨ve
mice, and mice bearing 5T2MM or 5T33MM cells. F. Total bone mineral density of naı¨ve mice, and 5T2MM or 5T33MM bearing mice. Statistical analysis
by Mann-Whitney U test. Data =mean6 S.E.M.
doi:10.1371/journal.pone.0041127.g001
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bearing mice (n = 12, naı¨ve control n = 9) and 4 weeks for the
5T33MM bearing mice (n = 7, naı¨ve control n= 9).
NOD/SCID Xenograft Model of Myeloma
Following whole body c-irradiation of NOD/SCID mice (3.0 Gy
per mouse, at a rate of 1Gy per 21.0 secs, using an IBL 437C 137Cs
gamma source, CIS BioInternational) at day 21, RPMI-8226
myeloma cells (American Type Culture Collection (ATCC),
Manassas, VA, USA) were injected subcutaneously (107 per mouse)
at day 0 (mice aged 8 weeks at day 0, and all male). The following
tumour cells were injected into irradiated mice: RPMI-8226/
hRANKL/eGFP (n= 8/group), RPMI- 8226/eGFP (n= 8/group),
RPMI-8226-wild-type (n= 7/group). Subcutaneous tumour pro-
gression was monitored via both eGFP-imaging (LightToolsH,
Synopsis Inc., Pasadena, CA) and caliper measurement and mice
were sacrificed once the tumour had reached 1 cm3. All procedures
involving these mice were undertaken at the University of Sheffield,
with written UK Home Office licence approval (ref. PPL402901).
Radiogaphic, Densitometric and MicroCT Analysis of Myelo-
ma Bone Disease To assess the number of osteolytic bone lesions
induced by the presence of myelomacells the femora and tibiae
were radiographed using a Faxitron x-ray system (Hewlett
Packard, McMinnville, Oregon). The radiographs were scanned
using a UMAX PowerLook 1100 scanner. Images were enlarged
using Adobe Photoshop 5.0 LE software and the numbers of lytic
bone lesions in the proximal tibiae and distal femora were counted
manually on the digital image. Total bone mineral density (BMD)
was measured by dual-energy x-ray absorptiometry (DXA) using a
PIXImus scanner (Lunar, Madison, WI).
In some studies tibiae were scanned using a microCT scanner
(Skyscan 1172) at 50 kV, 200 uA, using a detection pixel size of
4.3 um2 and a 0.5 mm aluminium filter, capturing images (62)
every 0.7u through 180u rotation. Reconstruction was performed
using Skyscan Recon software and images analysed using Skyscan
CT analysis software. A 1 mm3 volume of trabecular bone,
0.2 mm distal to the growth plate, was selected as a region of
interest (ROI), and trabecular volume as a proportion of tissue
volume (BV/TV, %), and trabecular number (Tb. N, mm21) was
assessed in this area.
Histomorphometric Analysis of Myeloma Bone Disease
The femora, tibiae, calvariae and lumbar vertebrae were
dissected free of soft tissues and processed for histological analysis.
Bones were decalcified in EDTA and embedded in paraffin.
Sections were cut and stained with haematoxylin and eosin.
Trabecular bone area as a proportion of the total area (Cn.Ar/
T.Ar,%) was determined in the distal femoral metaphysis and
proximal tibial metaphysis and lumbar vertebrae, on a minimum
of two separate sections, using a Leica QWin image analysis
system (Leica Microscope Systems, Milton Keynes, UK). The
medullary area in the calvariae was measured using the Leica
Qwin system and expressed as a proportion of total tissue area or
as an absolute area. To identify osteoclasts, sections were reacted
for the presence of tartrate resistant acid phosphatase (TRAP) and
counterstained with Mayer’s Haematoxylin. The number of
osteoclasts and/or the proportion of surface occupied by
osteoclasts on the cortical-endosteal bone surface (N.Oc/CE;
Oc.S/CE,%) were determined and, where appropriate, the
trabecular bone surface (N.Oc/Ca; Oc.S/Ca,%).
Measurement of Soluble RANKL and OPG in Serum
At sacrifice, blood samples were obtained from naı¨ve animals
(n = 8 as control for 5T2MM; n= 9 as control for 5T33MM) and
animals bearing 5T2MM (n=12) or 5T33MM (n= 7) tumour
Figure 2. 5T2MM, but not 5T33MMmurine myeloma cells promote osteoclast formation in C57BL/KaLwRij mice. A. Photomicrographs
of sections of the tibia reacted for TRAP activity from naive, 5T2MM and 5T33MM bearing mice showing the cortico-endosteal bone surface. TRAP-
positive osteoclasts are arrowed. Original magnification 640. B. The proportion of the cortical-endosteal bone surface occupied by osteoclasts,
expressed as the percentage of the total bone surface, from naive mice and mice bearing 5T2MM or 5T33MM myeloma cells. C. Photomicrographs of
sections of the tibia stained for TRAP activity from naive and 5T33MM bearing mice showing areas of trabecular bone. TRAP-positive osteoclasts are
arrowed. Original magnification640. D. The proportion of trabecular bone covered by osteoclasts in naı¨ve and 5T33MM bearing mice. Statistical
analysis by Mann-Whitney U test. Data =mean6 S.E.M.
doi:10.1371/journal.pone.0041127.g002
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cells. Serum was separated by centrifugation and murine
sRANKL, and murine OPG, were each measured by commer-
cially available ELISA (R&D Systems, Abingdon, UK), according
to the manufacturer’s instructions.
Production of RPMPI-8226/hRANKL/eGFP myeloma cells
cDNA encoding full-length human RANKL (hRANKL) was
originally isolated from the SAOS2 osteosarcoma cell line (ATCC,
Manassas, VA, USA). Its sequence corresponds to AF053712
(NCBI). hRANKL was cloned into the pCL10.1 bicistronic
expression vector upstream of the sequence encoding enhanced
green fluorescent protein (eGFP - Aequorea victoria), in which co-
expression is controlled by the murine stem cell virus promoter.
Self-inactivating lentiviral particles were produced as described
previously [30]. Briefly, 293T human embryonal kidney cells
(ATCC, Manassas, VA, USA) were co-transfected using a four
plasmid-system, which introduced lentiviral gag-pol genes, the
vesicular stomatitis virus envelope glycoprotein gene, reverse
transcriptase and the expression cassette from pCL10.1. Titre was
determined by limiting dilution on HeLa cells (ATCC, Manassas,
VA, USA). RPMI-8226 human myeloma cells were plated at
56104 cells per well in six-well plates, then exposed to viral
supernatant (MOI 10) for 12 hours, in the presence of polybrene
(8 mg.ml21). Transduced RPMI-8226 expressing hRANKL/
eGFP, or eGFP alone, were expanded in culture, and used for in
vitro and in vivo experiments.
Detection of hRANKL expression
Transduction was assessed using flow cytometry (anti-
hRANKL-PE, eBioscience Inc. Cat. No. 12-6619, mouse
IgG2b-PE isotype control Cat. No. 12-4732), end-point polymerase
chain reaction (PCR) (using primers directed at hRANKL: FOR 59-
TAGGAGAATTAAACAGGCCTTTC-39, REV 59-CAAAAAC-
TGGGGCTCAATC-39) and western blot (performed using anti-
hRANKL, R&D Systems Cat. No. AF626, 0.1 ug.ml21, and
detected with anti-goat-HRP, Dako Cat. No. P0449, 1/30000;
abcam anti-RNA polymerase II antibody, Cat. No. ab5408, 1/
2000, detected with anti-mouse-HRP, Amersham Biosciences Cat.
No. NA931V, 1/15000, was used as a loading control). ELISA,
directed at hRANKL (Biomedica Gruppe, Wien, Austria) (per-
formed according to the manufacturer’s instructions), was used to
quantify hRANKL in culture supernatant produced using trans-
duced cells, as well as control cells. Where appropriate, SaOS2 and
MG63 human osteoblast like cells (ATCC, Manassas, VA, USA)
were included as bone cell controls.
Determining whether over-expressed hRANKL is
biologically active in vitro
Freshly isolated mouse peripheral blood mononuclear cells were
plated in medium conditioned with RPMI-8226/hRANKL/eGFP
cells, and supplemented with rmM-CSF at 25 ng.ml21 (using 6-
well plates). Media conditioned using either wild-type or eGFP-
transduced cells were used as controls. Alpha-MEM, supplement-
ed with rmM-CSF (see above) and rhRANKL at 0.5 ngml21, in
order to match the concentration detected in the conditioned
medium, was included as a positive control. The number of
TRAP-positive multinuclear (3+) cells was determined at 7, 14 and
21-day time points, via light microscopy.
In order to determine whether the multinuclear TRAP-positive
cells could resorb bone, freshly-isolated mouse PBMC were
cultured on dentine slices in medium conditioned with RPMI-
8226/hRANKL/eGFP, as above (using 96-well plates). eGFP-only
and wild-type controls were also included. At 21-days, slices were
stained, using toluidine blue, and resorption pits visualised and
scored, using light microscopy.
Statistical Analysis
Data were expressed as the mean 6 SEM. Comparison
between groups was performed by Mann-Whitney U test, Chi-
square analysis or Student’s unpaired t test, as appropriate.
Comparisons between distributions were performed using a
Kolmogorov-Smirnov test.
Results
5T2MM but not 5T33MM Myeloma Cells Promote the
Development of Myeloma Bone Disease in the Tibiae and
Femora in vivo
Injection of 5T2MM and 5T33MM cells into the tail vein of
syngeneic C57BL/KaLwRij mice resulted in growth of myeloma
cells in the bone marrow. Both 5T2MM and 5T33MM bearing
mice had detectable levels of paraprotein in the serum
(1.2560.25 g.L21, at 12 weeks, in the case of the 5T2MM-
bearing mice). MicroCT, as well as radiographic analysis, of the
long bones of mice bearing 5T2MM cells was used to demonstrate
the presence of osteolytic bone lesions in the tibia and femur,
which are areas in which increased osteoclast activity results in
focal bone loss (Figure 1A–C). On a digitised radiographic image
of a mouse tibia, the osteolytic bone lesions can be distinguished
from surrounding intact bone as darker regions in which the bone
has been removed. Assessment of the numbers of lesions in the
Figure 3. Serum concentrations of sRANKL and OPG are
abnormally regulated in mice bearing 5T2MM and 5T33MM
cells, respectively. Serum concentrations of sRANKL and OPG are
abnormally regulated in mice bearing 5T2MM and 5T33MM cells,
respectively. A. Serum concentrations of sRANKL in naive mice and mice
bearing 5T2MM or 5T33MM cells. B. Serum concentrations of OPG in
naive animals and animals bearing 5T2MM or 5T33MM cells. Statistical
analysis by Mann-Whitney U test. Data =mean6 S.E.M.
doi:10.1371/journal.pone.0041127.g003
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tibia showed a significant increase in 5T2MM bearing animals
when compared to naı¨ve animals (p,0.05)(Figure 1D), whereas no
lesions were observed in mice bearing 5T33MM cells (Figures 1C
and 1D). Histomorphometric analysis of the long bones of
5T2MM bearing mice demonstrated a significant decrease in
the trabecular bone area in the tibia and femur when compared to
un-injected naı¨ve animals (p,0.05). In contrast, trabecular bone
area in mice bearing 5T33MM cells was not significantly different
from naı¨ve, uninjected mice (Figure 1E). Total BMD in the tibiae
was also lower in 5T2MM bearing mice when compared to naı¨ve,
un-injected animals (p,0.01). There was no difference in total
BMD in the tibiae in naı¨ve mice and mice bearing 5T33MM cells
(Figure 1F).
Histomorphometric analysis demonstrated that the proportion
of cortico-endosteal bone surface covered by osteoclasts was
significantly increased in 5T2MM bearing animals when com-
pared to control (p,0.05). In contrast, osteoclasts were not
identified on the cortico-endosteal surface of naı¨ve mice or mice
bearing 5T33MM cells (Figure 2A and 2B). Analysis of the
trabecular bone surfaces of 5T33MM bearing mice showed a
Figure 4. 5T2MM bearing mice have increased bone loss in the lumbar vertebrae and calvariae. A. Photomicrographs of the vertebrae
from naı¨ve and 5T2MM bearing mice. Tumour infiltration is identified with black arrows. B. The proportion of trabecular bone area in the vertebrae
from naı¨ve and 5T2MM-bearing mice. C. Photomicrographs of the calvariae of naı¨ve and 5T2MM bearing mice. Medullary spaces are identified with
black arrows, and OC with yellow arrows. Non tumour-containing spaces are shown. D. The proportion of medullary area as a percentage of total
tissue area in naı¨ve and 5T2MM-bearing mice. E. Distribution of medullary spaces in naı¨ve and 5T2MM-bearing mice, showing significant differences
in distribution (KS test, p,0.02). Chi-square analysis demonstrated that 5T2MM-bearing mice had significantly fewer, smaller spaces and more, larger
spaces than naı¨ve mice (p,0.05). Data =mean6 S.E.M. (B and D).
doi:10.1371/journal.pone.0041127.g004
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decrease in the proportion of trabecular bone surface covered by
osteoclasts (p,0.01) (Figure 2C and 2D). It was not possible to
analyse the trabecular bone surface occupied by osteoclasts in
5T2MM bearing mice as the trabecular bone had been almost
completely resorbed.
Serum Concentrations of Soluble RANKL and OPG Are
Abnormally Regulated in 5T2MM and 5T33MM Bearing
Mice Compared to Non-Tumour Bearing, Naı¨ve Mice
We next measured serum concentrations of sRANKL and OPG
in mice bearing 5T2MM and 5T33MM cells and compared them
to non-tumour bearing, naı¨ve mice. sRANKL was not detectable
in the serum of naı¨ve mice or mice bearing 5T33MM cells.
However, significant concentrations of sRANKL were measured
in the serum of mice bearing 5T2MM cells (379.0658.4 pg/ml,
shown in Figure 3A). In contrast, serum concentrations of OPG in
5T2MM bearing animals and naı¨ve animals were not significantly
different (1.8660.08 and 1.7760.13 ng/ml respectively), whereas
serum OPG was significantly increased in mice bearing 5T33MM
cells when compared to naı¨ve, un-injected animals (14.9761.09
and 1.3360.13 ng/ml respectively, p,0.005) (Figure 3B). There
was no significant correlation between sRANKL and OPG in
5T2MM bearing mice.
5T2MM Bearing Mice Have Increased Bone Loss in the
Vertebrae and Calvariae
High serum concentration of sRANKL would be consistent with
the bone loss observed in the tibia and the development of
osteolytic bone lesions. However, alterations in circulating
sRANKL would also be expected to promote more generalised
bone loss. We therefore examined bones isolated from other sites
for evidence of generalised osteoporosis in 5T2MM bearing mice.
Histomorphometric examination of lumbar vertebrae demonstrat-
ed a significant decrease in trabecular bone in 5T2MM bearing
mice compared to non-tumour bearing, naı¨ve mice (Figure 4A and
4B), although, bone loss was also associated with significant
infiltration of 5T2MM tumour cells. However, analysis of the
medullary area in the calvariae demonstrated a significant increase
in area in 5T2MM bearing mice compared to naı¨ve mice
(p,0.05), consistent with increased bone loss (Figure 4C, 4D). In
the 5T2MM-bearing mice tumour infiltration was seen in only a
limited number of medullary spaces (13%). Comparison of the
medullary spaces from naı¨ve and 5T2MM-bearing mice, but
excluding those showing evidence of tumour infiltration, demon-
strated a significant difference in the distribution of medullary
space size (p,0.02) (Figure 4E). Chi-square analysis demonstrated
that 5T2MM-bearing mice had significantly more, larger spaces
and fewer, smaller spaces than naı¨ve mice (p,0.05). In contrast,
5T33MM bearing mice showed no difference in the distribution of
their medullary spaces when compared to naı¨ve mice (p = 0.42;
data not shown) and Chi-square analysis failed to show any
difference in the proportion of larger medullary spaces when
compared to naı¨ve mice.
RPMI-8226/hRANKL/eGFP human myeloma cells express
biologically active soluble hRANKL
To determine whether myeloma cell derived RANKL could
induce systemic bone loss we generated myeloma cells over-
expressing hRANKL (RPMI-8226/hRANKL/eGFP). Using end-
Figure 5. RPMI-8226/hRANKL/eGFP cells express hRANKL. A. End-point PCR demonstrating that human RANKL mRNA is present in RPMI-
8226/hRANKL/eGFP cells (labeled hRANKL). hRANKL mRNA was not detected in the corresponding eGFP-only control cell line (labeled eGFP), or in
wild-type cells (labeled WT). No product was amplified in the absence of RNA (labelled no RNA) or the superscript enzyme (labeled SS-). B. Western
Blot analysis detected the hRANKL monomer (,34 kDa) in culture supernatant from RPMI-8226/hRANKL/eGFP cells - red outline. (i) Wild-type and
eGFP-only expressing cell controls are included, and the rhRANKL antibody-control is also shown (,23 kDa). (ii) Ribosomal RNA loading controls were
included. C. Flow cytometric analysis of the RPMI-8226/hRANKL/eGFP-expressing cells. Representative plots showing cells stained with anti-hRANKL-
PE antibody (eBioScience, 1/50 dilution) (transparent profile) and isotype control (solid profile).
doi:10.1371/journal.pone.0041127.g005
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point PCR, hRANKL mRNA was detected in RPMI-8226/
hRANKL/eGFP (Figure 5A). In contrast, no expression was
detected in the vector-only control, or wild-type cells. Following
western blot, normalised using ribosomal RNA loading controls,
hRANKL protein was detected in culture medium conditioned by
RPMI-8226/hRANKL/eGFP cells (Figure 5B), but not in
medium conditioned by wild-type or vector only control cells, as
well as medium conditioned using osteoblast cell lines SAOS2 and
MG63. In addition, flow cytometric analysis, using an antibody
directed at hRANKL along with its corresponding isotype control,
demonstrates that the RPMI-8226/hRANKL/eGFP cells express
hRANKL at the cell surface (Figure 5C), whereas the RPMI-
8226/eGFP and wild-type cells do not. Soluble hRANKL was
detected in medium conditioned using the RPMI-8226/
hRANKL/eGFP cells (circa 0.4 ng.ml21), determined by ELISA.
Soluble RANKL was not detected in wild-type or RPMI-8226/
eGFP control cells (Figure 6A).
When freshly isolated mouse PBMC were cultured in medium
conditioned with RPMI-8226/hRANKL/eGFP cells, multinucle-
ate TRAP-positive cells were observed. No such cells formed in the
cultures treated with medium conditioned using RPMI-8226/
eGFP cells (Figure 6B). In separate in vitro experiments, where
mouse PBMC were cultured on dentine slices, in the presence of
medium conditioned by RPMI-8226/hRANKL/eGFP cells,
resorption trails were observed (Figure 6C). No pits were observed
on dentine slices cultured with medium conditioned using RPMI-
8226/eGFP control cells (Figure 6C).
RPMI-8226/hRANKL/eGFP-bearing mice have increased
osteoclast number, elevated serum soluble RANKL and
reduced trabecular bone volume and number
Sub-cutaneous injection of NOD/SCID mice with RPMI-
8226/hRANKL/eGFP, or RPMI-8226/eGFP cells, resulted in
palpable tumour development in all mice. The mice bearing
RPMI-8226/hRANKL/eGFP cells also exhibited increased serum
soluble hRANKL (p,0.05) compared to RPMI-8226/eGFP cells
(Figure 7A), although not all mice had detectable sRANKL.
Following sacrifice, histological analysis of the tibiae from all mice
showed that marrow space was not infiltrated with myeloma cells.
However, histomorphometric analysis demonstrated that RPMI-
8226/hRANKL/eGFP-bearing mice exhibited a three-fold in-
crease in osteoclast number (p,0.05) along the cortico-endosteal
surface compared to RPMI-8226/eGFP-bearing mice (Figure 7B
and 7C). MicroCT analysis of tibiae of RPMI-8226/hRANKL/
eGFP-bearing mice, with detectable sRANKL in the serum, was
associated with reduced trabecular bone volume (27%, p,0.05)
(Figure 7D and 7E), decreased trabecular number (29%, p,0.05)
(Figure 7F), and increased trabecular thickness (8%, p,0.05 - data
not shown).
Discussion
In the present study we examined the ability of two syngeneic
models of multiple myeloma, the 5T2MM and the 5T33MM
models, to cause both osteolytic bone disease and osteoporosis. In
5T2MM bearing mice this was characterised by the presence of
osteolytic bone lesions on radiographs, loss of trabecular bone, a
reduction in total bone mineral density and an increase in the
proportion of bone surface covered by osteoclasts. This mimics the
features of the bone disease seen in patients with multiple
myeloma. In contrast, injection of 5T33MM cells had little effect
on bone. 5T33MM cells did not promote the development of
osteolytic bone lesions, had no effect on trabecular bone area or
total bone mineral density and did not increase osteoclast
formation. Indeed, histomorphometric analysis demonstrated that
osteoclast surface on trabecular bone was significantly reduced in
mice bearing 5T33MM cells. These data contrast with a previous
study in which 5T33MM cells were reported to promote the
development of a myeloma bone disease [31]. The reason for the
difference between the two studies is unclear. However, the
5T33MM cells have been maintained independently, in different
laboratories for many years and therefore, this may reflect the
selection of different clones of 5T33MM cells over time.
In addition to focal osteolytic bone lesions, generalised
osteoporosis was observed in the bones of 5T2MM bearing mice
in which tumour cells were not present. In the calvariae of these
Figure 6. Transduced RPMI-8226 human myeloma cells express
biologically active soluble hRANKL. A. shRANKL is detected by
ELISA (Biomedica Gruppe, Wien, Austria), at a concentration of
,0.4 ng.ml21, in medium conditioned using RPMI-8226/hRANKL/eGFP
cells, but not in controls. B. Multinucleated TRAP-positive cells
(osteoclasts) formed in a culture of mouse PBMC cultured in medium
conditioned with RPMI-8226/hRANKL/eGFP, supplemented with M-CSF
(50 ng.ml21). No osteoclasts were observed in control wells containing
conditioned media from wild-type cells (data not shown) or RPMI-8226/
eGFP. C. Resorption trails formed on the surface of dentine slices
cultured in the presence of freshly prepared mouse PBMC, using
medium conditioned with RPMI-8226/hRANKL/eGFP. No trails formed
on slices cultured in medium conditioned by RPMI-8226/eGFP (or wild-
type - data not shown). Statistical analysis performed using unpaired t-
test. Data =mean6 S.E.M.
doi:10.1371/journal.pone.0041127.g006
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mice, significant bone loss was observed, which is consistent with
the hypothesis that bone loss also occurs independently of local
induction by tumour cells, and results from systemic induction of
osteoclastogenesis. In support of this, studies have shown that a
significant proportion of patients with multiple myeloma develop
osteopenia or osteoporosis independent of lytic bone lesions [2].
The molecular mechanism responsible for the development of
osteoporosis in myeloma is unknown.
Measurement of sRANKL in serum showed that 5T2MM-
bearing mice had high circulating levels of sRANKL in all tumour-
bearing mice. In contrast, sRANKL was not detectable in the
serum of naı¨ve mice, or mice bearing 5T33MM cells. This is
consistent with the demonstration of increased serum concentra-
tions of sRANKL in patients with myeloma and that an increase in
the ratio of RANKL/OPG is associated with lytic bone lesions
[32]. The source of sRANKL remains unclear, but may reflect
production by cells within the bone marrow microenvironment,
such as stromal cells and T-cells, or production by 5T2MM cells,
since we have shown previously that these cells express RANKL
[10]. Furthermore, the mechanism responsible for generating
sRANKL is unknown, but may include proteolytic cleavage of a
membrane-bound RANKL isoform, as myeloma cells can shed
membrane bound molecules [33,34] and express ADAM17, a
proteinase capable of shedding RANKL [35]. Alternatively,
circulating sRANKL may be generated by differential mRNA
splicing, which has been reported in myeloma cells [13].
Treatment of the RPMI8226/eGFP/hRANKL cells with phorbol
12-myristate 13-acetate, which has been shown to activate
membrane shedding activity, had no effect on membrane RANKL
expression and did not increase sRANKL in the culture super-
natent (data not shown). This may argue against proteolytic
processing of the membrane bound form being the main
mechanism of production. Irrespective of the source, these data
support the notion that sRANKL, as a key regulator of osteoclastic
bone resorption, drives the development of osteoporosis.
Serum concentrations of OPG were unchanged in 5T2MM-
bearing mice, but were elevated in those mice bearing 5T33MM
cells. This may account for the observed inhibition of osteoclast
formation, the lack of detectable bone disease seen in the
5T33MM model and explain the difference between the present
study and data reported by Garrett et al. [31]. The failure to affect
BMD in 5T33MM bearing mice is likely to reflect the short
timeframe of this model (4 weeks) and the relatively small
contribution attributable to trabecular bone.
In order to investigate the hypothesis that osteoporosis is caused,
at least in part, by elevated systemic sRANKL, experiments were
performed using a mouse xenograft system in which the tumour
cells were engineered to over-express hRANKL. Mice were injected
subcutaneously with RPMI-8226/hRANKL/eGFP cells and
growth shown to be restricted to the site of implant. Significant
increases in serum sRANKL were observed in mice bearing RPMI-
8226/hRANKL/eGFP cells, compared to control, myeloma cell
bearing animals. Histological examination demonstrated that this
increase was associated with elevated numbers of osteoclasts in
bones from RPMI-8226/hRANKL/eGFP bearing animals, despite
the absence of tumour cells in the bone marrow. These findings are
associated with a significant reduction in bone volume and
trabecular number in those animals. Taken together these data
Figure 7. RPMI-8226/hRANKL/eGFP-bearing mice have elevated serum soluble RANKL, increased osteoclast number and reduced
trabecular bone volume. A. ELISA demonstrating significantly increased serum sRANKL in mice bearing RPMI-8226/hRANKL/eGFP cells, compared
to RPMI-8226/eGFP-bearing animals, as well as wild-type cells (data not shown). B. Photomicrographs of sections of mouse tibiae demonstrating that
mice bearing RPMI-8226/hRANKL/eGFP (ii) have increased OC number at the CE-surface, compared to mice bearing RPMI-8226/eGFP control cells (i).
OC are arrowed. Original magnification640. C. Increased OC number is observed at the CE surface in mice bearing RPMI-8226/hRANKL/eGFP cells. D.
MicroCT images showing reduced bone volume in tibiae of mice bearing RPMI-8226/hRANKL/eGFP, as opposed to wild-type cells. E. RPMI-8226/
hRANKL/eGFP-treated mice have decreased trabecular bone volume (27%) when compared to RPMI-8226/eGFP cell-bearing animals. F. RPMI-8226/
hRANKL/eGFP-treated mice have reduced trabecular number (29%), when compared to RPMI-8226/eGFP-bearing animals. Statistical analysis
performed using unpaired t-test. Data =mean6 S.E.M.
doi:10.1371/journal.pone.0041127.g007
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demonstrate that RANKL expressed bymyeloma cells, and released
as soluble RANKL, stimulates osteoclast formation and promotes
bone loss at distant sites in the skeleton. In support of this, both
OPG [10] and a soluble receptor activator of NFkB-Fc construct
(data not shown) were able to prevent osteoclast formation and the
development of bone disease in the 5T2MM model.
In conclusion, using mouse models of myeloma we have been
able to demonstrate that myeloma is associated with both focal
osteolytic bone disease and osteoporosis, and this is associated with
increased serum concentrations of sRANKL. Furthermore,
myeloma cells that express RANKL also produce soluble RANKL
in vivo and this is able to promote osteoclast formation and
osteoporosis. This supports the hypothesis that elevated serum
soluble RANKL contributes to the development of osteoporosis in
myeloma. Therefore, inhibiting RANKL may have therapeutic
potential not only for the treatment of osteolytic bone lesions but
also the generalised osteoporosis. Furthermore, this raises the
possibility of using novel treatments such as the monoclonal
antibody Denosumab, a fully human monoclonal antibody that
targets the RANK-RANKL interaction [36]. This agent has been
in development for the treatment of osteolytic bone disease in
patients with multiple myeloma, for the treatment of bone disease
in bone metastases and for osteoporosis in post- menopausal
women [37,38,39]. Its role in the treatment of osteoporosis in
myeloma is unclear but the data presented would argue that
consideration should be given to its use in this setting. Thus,
treatments such as Denosumab, which have been used successfully
for the treatment of post-menopausal osteoporosis, could be
considered as potential treatment of both the focal osteolytic
disease [39,40] and the generalised osteoporosis seen in patients
with multiple myeloma.
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